MedTrace Logo

UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD

NCT02978391 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2022-04-08

No results posted yet for this study

Summary

UI-EWD (NextBiomedical Co, Incheon, South Korea), a new hemostatic powder for endoscopic treatment of high-risk bleeding peptic ulcers and bleeding after ESD/EMR.

Conditions

  • Upper Gastrointestinal Bleeding

Interventions

DEVICE

UI-EWD Hemostatic system

Adhesive endoscopic hemostats, powder type

DRUG

epinephrine endoscopic injection (conventional therapy)

endoscopic submucosal injection of epinephrine (1: 10,000)

Sponsors & Collaborators

  • Next Biomedical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yong-Woon Shin · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-23
Primary Completion
2016-11-30
Completion
2017-09-18

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02978391 on ClinicalTrials.gov